Originally published as JCO Early Release 10.1200/JCO.2005.13.755 on September 12 2005

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Patt, D. A. Articles by Giordano, S. H. Search for Related Content PubMed PubMed Citation Articles by Patt, D. A. Articles by Giordano, S. H. Related Articles Related Editorial Social Bookmarking                            What's this?

Cardiac Morbidity of Adjuvant Radiotherapy for Breast Cancer

From the Departments of Medical Oncology, Radiation Oncology, and Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston; and Department of Internal Medicine and Sealy Center on Aging, University of Texas Medical Branch at Galveston, Galveston, TX

Address reprint requests to Sharon H. Giordano, MD, MPH, 1515 Holcombe Blvd, Box 424, Houston, TX 77030; e-mail: sgiordan{at}mdanderson.org

PURPOSE: Adjuvant breast irradiation has been associated with an increase in cardiac mortality, because left-sided breast radiation can produce cardiac damage. The purpose of this study was to determine whether modern adjuvant radiotherapy is associated with increased risk of cardiac morbidity.

PATIENTS AND METHODS: Data from the Surveillance, Epidemiology, and End Results–Medicare database were used for women who were diagnosed with nonmetastatic breast cancer from 1986 to 1993, had known disease laterality, underwent breast surgery, and received adjuvant radiotherapy. The Cox proportional-hazards model was used to compare patients with left- versus right-sided breast cancer for the end points of hospitalization with the following discharge diagnoses (International Classification of Diseases, 9th Revision codes): ischemic heart disease (410-414, 36.0, and 36.1), valvular heart disease (394-397, 424, 35), congestive heart failure (428, 402.01, 402.11, 402.91, and 425), and conduction abnormalities (426, 427, 37.7-37.8, and 37.94-37.99).

RESULTS: Eight thousand three hundred sixty-three patients had left-sided breast cancer, and 7,907 had right-sided breast cancer. Mean follow-up was 9.5 years (range, 0 to 15 years). There were no significant differences in patients with left- versus right-sided cancers for hospitalization for ischemic heart disease (9.9% v 9.7%), valvular heart disease (2.9% v 2.8%), conduction abnormalities (9.7% v 9.6%), or heart failure (9.7% v 9.7%). The adjusted hazard ratio for left- versus right-sided breast cancer was 1.05 (95% CI, 0.94 to 1.16) for ischemic heart disease, 1.07 (95% CI, 0.89 to 1.30) for valvular heart disease, 1.07 (95% CI, 0.96 to 1.19) for conduction abnormalities, and 1.05 (95% CI, 0.95 to 1.17) for heart failure.

CONCLUSION: With up to 15 years of follow-up there were no significant differences in cardiac morbidity after radiation for left- versus right-sided breast cancer.

Supported by National Institutes of Health Grant No. 1K07 CA 109064-01 (S.H.G.).

Presented at the 2004 San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-11, 2004 (abstr 4063).

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Editorial

• Radiation-Induced Heart Disease: Vigilance Is Still Required
  Robert G. Prosnitz and Lawrence B. Marks
  JCO 2005 23: 7391-7394 [Full Text]

This article has been cited by other articles:

				M. Y. Halyard, T. M. Pisansky, A. C. Dueck, V. Suman, L. Pierce, L. Solin, L. Marks, N. Davidson, S. Martino, P. Kaufman, et al. Radiotherapy and Adjuvant Trastuzumab in Operable Breast Cancer: Tolerability and Adverse Event Data From the NCCTG Phase III Trial N9831 J. Clin. Oncol., June 1, 2009; 27(16): 2638 - 2644. [Abstract] [Full Text] [PDF]

				J. S. Mandelblatt and R. Silliman Hanging in the Balance: Making Decisions About the Benefits and Harms of Breast Cancer Screening Among the Oldest Old Without a Safety Net of Scientific Evidence J. Clin. Oncol., February 1, 2009; 27(4): 487 - 490. [Full Text] [PDF]

				D. J. Lenihan and F. J. Esteva Multidisciplinary Strategy for Managing Cardiovascular Risks When Treating Patients with Early Breast Cancer Oncologist, December 1, 2008; 13(12): 1224 - 1234. [Abstract] [Full Text] [PDF]

				G. L. Smith, B. D. Smith, T. A. Buchholz, S. H. Giordano, A. S. Garden, W. A. Woodward, H. M. Krumholz, R. S. Weber, K.-K. Ang, and D. I. Rosenthal Cerebrovascular Disease Risk in Older Head and Neck Cancer Patients After Radiotherapy J. Clin. Oncol., November 1, 2008; 26(31): 5119 - 5125. [Abstract] [Full Text] [PDF]

				A. H Wu Cardiotoxic drugs: clinical monitoring and decision making Heart, November 1, 2008; 94(11): 1503 - 1509. [Full Text] [PDF]

				B. R.J. H. Bird and S. M. Swain Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems Clin. Cancer Res., January 1, 2008; 14(1): 14 - 24. [Abstract] [Full Text] [PDF]

				L. W. Jones, M. J. Haykowsky, J. J. Swartz, P. S. Douglas, and J. R. Mackey Early Breast Cancer Therapy and Cardiovascular Injury J. Am. Coll. Cardiol., October 9, 2007; 50(15): 1435 - 1441. [Abstract] [Full Text] [PDF]

				L. W. Jones, M. Haykowsky, E. N. Pituskin, N. G. Jendzjowsky, C. R. Tomczak, R. G. Haennel, and J. R. Mackey Cardiovascular Reserve and Risk Profile of Postmenopausal Women After Chemoendocrine Therapy for Hormone Receptor Positive Operable Breast Cancer Oncologist, October 1, 2007; 12(10): 1156 - 1164. [Abstract] [Full Text] [PDF]

				J. R. Carver, C. L. Shapiro, A. Ng, L. Jacobs, C. Schwartz, K. S. Virgo, K. L. Hagerty, M. R. Somerfield, D. J. Vaughn, and for the ASCO Cancer Survivorship Expert Panel American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects J. Clin. Oncol., September 1, 2007; 25(25): 3991 - 4008. [Abstract] [Full Text] [PDF]

				S. C. Formenti, D. Gidea-Addeo, J. D. Goldberg, D. F. Roses, A. Guth, B. S. Rosenstein, and K. J. DeWyngaert Phase I-II Trial of Prone Accelerated Intensity Modulated Radiation Therapy to the Breast to Optimally Spare Normal Tissue J. Clin. Oncol., June 1, 2007; 25(16): 2236 - 2242. [Abstract] [Full Text] [PDF]

				S. H. Giordano and G. N. Hortobagyi Local Recurrence or Cardiovascular Disease: Pay Now or Later J Natl Cancer Inst, March 7, 2007; 99(5): 340 - 341. [Full Text] [PDF]

				M. J. Hooning, A. Botma, B. M. P. Aleman, M. H. A. Baaijens, H. Bartelink, J. G. M. Klijn, C. W. Taylor, and F. E. van Leeuwen Long-Term Risk of Cardiovascular Disease in 10-Year Survivors of Breast Cancer J Natl Cancer Inst, March 7, 2007; 99(5): 365 - 375. [Abstract] [Full Text] [PDF]

				E. E.R. Harris, C. Correa, W.-T. Hwang, J. Liao, H. I. Litt, V. A. Ferrari, and L. J. Solin Late Cardiac Mortality and Morbidity in Early-Stage Breast Cancer Patients After Breast-Conservation Treatment J. Clin. Oncol., September 1, 2006; 24(25): 4100 - 4106. [Abstract] [Full Text] [PDF]

				A. Recht Which Breast Cancer Patients Should Really Worry About Radiation-Induced Heart Disease--And How Much? J. Clin. Oncol., September 1, 2006; 24(25): 4059 - 4061. [Full Text] [PDF]

				J. S. Wong, S. C. Lester, and B. L. Smith In Reply: J. Clin. Oncol., August 10, 2006; 24(23): 3811 - 3812. [Full Text] [PDF]

				R. G. Prosnitz and L. B. Marks Radiation-Induced Heart Disease: Vigilance Is Still Required J. Clin. Oncol., October 20, 2005; 23(30): 7391 - 7394. [Full Text] [PDF]